drugset / Trial / NCT03107416

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

NCT03107416

Phase 1/2 Active not recruiting 30 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.

Timeline

Start
2017-04-05
Primary completion
2027-04-05
Completion
2027-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bumetanide Small molecule 0.01 mg/kg Other
Subject Bumetanide Small molecule 0.02 mg/kg Other
Subject Bumetanide Small molecule 0.04 mg/kg Other